Aspirine en prévention cardiovasculaire primaire : la fin d’une époque ? [Aspirin for primary cardiovascular prevention : the end of an era ?]

Details

Ressource 1Download: RMS_790-2_1464.pdf (818.89 [Ko])
State: Public
Version: Final published version
License: CC BY-NC-ND 4.0
Serval ID
serval:BIB_7A4F74482DF5
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Aspirine en prévention cardiovasculaire primaire : la fin d’une époque ? [Aspirin for primary cardiovascular prevention : the end of an era ?]
Journal
Revue medicale suisse
Author(s)
Ravach G., Fournier S., Mazzolai L., Nanchen D.
ISSN
1660-9379 (Print)
ISSN-L
1660-9379
Publication state
Published
Issued date
04/03/2020
Peer-reviewed
Oui
Volume
16
Number
684
Pages
459-462
Language
french
Notes
Publication types: Journal Article ; Review
Publication Status: ppublish
Abstract
Low-dose aspirin in primary prevention of cardiovascular disease is still debated. Recent clinical trials of aspirin vs placebo reported an unfavourable risk-benefit ratio with an increase in major bleedings without reduction on the occurrence of non-fatal cardiovascular events. These studies also highlight that current cardiovascular risk calculators overestimate cardiovascular risk, which is probably related to the improvement in the management of cardiovascular risk factors over the last decades. In accordance with European cardiovascular prevention recommendations, aspirin should not be prescribed for the primary prevention of cardiovascular disease.
Keywords
Aspirin/administration & dosage, Aspirin/therapeutic use, Cardiovascular Diseases/prevention & control, Hemorrhage/chemically induced, Humans, Primary Prevention/methods, Primary Prevention/trends, Risk Assessment
Pubmed
Create date
19/03/2020 16:29
Last modification date
20/08/2022 7:11
Usage data